Weight-loss injection eligibility below BMI 27 is often discussed online, but starting treatment at that BMI and reaching it after treatment are different situations. The answer also depends on the medicine and why it is prescribed. Licensed weight management, a diabetes indication and NHS funding rules answer different questions; current BMI alone cannot classify a person’s treatment as off-label.

Mounjaro eligibility uses initial BMI and includes maintenance

The current UK Mounjaro product information covers weight management, including weight loss and weight maintenance, in adults with an initial BMI of at least 30, or at least 27 with a weight-related condition, alongside reduced-calorie eating and increased physical activity. Starting treatment solely for weight management with an initial BMI below the indicated threshold is different from continuing appropriate maintenance after an eligible start. A person whose BMI falls below 27 after successful treatment is not automatically outside the licensed indication. Ongoing suitability should be reviewed with the prescriber. The separate diabetes indication should not be judged against the weight-management BMI threshold.

What does off-label prescribing mean?

Off-label use means using a licensed medicine outside the terms of its licence. It is distinct from buying an unapproved research product. The GMC’s prescribing guidance requires an appropriate evidence basis, responsibility for care and an explanation to the patient where a medicine is used outside its licence. An online anecdote is not that assessment.

Licensed eligibility is different from NHS access

The NICE recommendations for tirzepatide include separate criteria for NHS use and recognise lower BMI thresholds for some ethnic backgrounds. NHS implementation can also be phased. A person may meet the medicine’s licensed indication without qualifying for a particular funded service, and a general web calculator cannot resolve that difference.

Discuss the treatment goal, health conditions, medicines already being taken and the relevant indication with a qualified prescriber. If an option is outside its licence, ask what evidence supports that use, what uncertainties remain and how it would be monitored.

Questions that are more useful than finding a supplier

  • Is this about starting weight-management treatment, continuing maintenance or treating diabetes?
  • How does my initial BMI, rather than only my current BMI, relate to the licensed indication?
  • If treatment would be off-label, why is it being considered and what alternatives exist?
  • Who will assess risks, provide follow-up and respond to problems?

More science explainers and Svelta Labs information are available at https://sveltalabs.com.

This article explains eligibility and prescribing terms; it does not recommend off-label treatment. Research-use peptides are not an alternative route around prescription requirements.

Sources

MHRA: Mounjaro weight-management authorisation, 8 November 2023: https://www.gov.uk/government/news/mhra-authorises-diabetes-drug-mounjaro-tirzepatide-for-weight-management-and-weight-loss.

Eli Lilly: UK Mounjaro KwikPen Summary of Product Characteristics, section 4.1: https://www.medicines.org.uk/emc/product/15484/smpc.

General Medical Council: Prescribing unlicensed medicines: https://www.gmc-uk.org/professional-standards/the-professional-standards/good-practice-in-prescribing-and-managing-medicines-and-devices/prescribing-unlicensed-medicines.

NICE TA1026: Tirzepatide recommendations: https://www.nice.org.uk/guidance/TA1026/chapter/1-Recommendations.